nisoxetine has been researched along with Disease Models, Animal in 9 studies
nisoxetine: potent inhibitor for norepinephrine uptake into rat brain synaptosomes & brain; NM refers to (+-)-isomer; RN given refers to parent cpd; structure
nisoxetine : A secondary amino compound that is N-methyl-3-phenylpropan-1-amine substituted at position 3 by a 2-methoxyphenoxy group.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of rats with monocrotaline (MCT) leads to pulmonary hypertension, right ventricular (RV) hypertrophy, and finally to RV heart failure." | 3.71 | Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac beta-adrenoceptor system in experimental heart failure. ( Beilfuss, A; Brandt, K; Brodde, OE; Heinroth-Hoffmann, I; Leineweber, K; Pönicke, K; Wludyka, B, 2002) |
| "Treatment with methylphenidate or nisoxetine ameliorated CAR impairments in DAT-KO mice." | 1.39 | Impaired cliff avoidance reaction in dopamine transporter knockout mice. ( Hall, FS; Kasahara, Y; Kobayashi, H; Numachi, Y; Sakakibara, Y; Sora, I; Uchiumi, O; Uhl, GR; Yamashita, M; Yoshida, S, 2013) |
| " Overall, the dose-response and time-of-recovery relationships for altered NET expression matched those for production of antidepressant-like effects on behavior." | 1.35 | Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine. ( Baros, AM; Bondi, CO; Lapiz, MD; Morilak, DA; O'Donnell, JM; Zhang, HT; Zhao, Z, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Shao, L | 1 |
| Wang, F | 1 |
| Malcolm, SC | 1 |
| Ma, J | 1 |
| Hewitt, MC | 1 |
| Campbell, UC | 1 |
| Bush, LR | 1 |
| Spicer, NA | 1 |
| Engel, SR | 1 |
| Saraswat, LD | 1 |
| Hardy, LW | 1 |
| Koch, P | 1 |
| Schreiber, R | 1 |
| Spear, KL | 1 |
| Varney, MA | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Jin, ZL | 1 |
| Gao, N | 1 |
| Zhang, JR | 1 |
| Li, XR | 1 |
| Chen, HX | 1 |
| Xiong, J | 1 |
| Li, YF | 1 |
| Tang, Y | 1 |
| Kasahara, Y | 2 |
| Kubo, Y | 1 |
| Sora, I | 2 |
| Yamashita, M | 1 |
| Sakakibara, Y | 1 |
| Hall, FS | 1 |
| Numachi, Y | 1 |
| Yoshida, S | 1 |
| Kobayashi, H | 1 |
| Uchiumi, O | 1 |
| Uhl, GR | 1 |
| Leineweber, K | 1 |
| Brandt, K | 1 |
| Wludyka, B | 1 |
| Beilfuss, A | 1 |
| Pönicke, K | 1 |
| Heinroth-Hoffmann, I | 1 |
| Brodde, OE | 1 |
| Zhao, Z | 1 |
| Baros, AM | 1 |
| Zhang, HT | 1 |
| Lapiz, MD | 1 |
| Bondi, CO | 1 |
| Morilak, DA | 1 |
| O'Donnell, JM | 1 |
| Strazielle, C | 1 |
| Lalonde, R | 1 |
| Hébert, C | 1 |
| Reader, TA | 1 |
1 review available for nisoxetine and Disease Models, Animal
| Article | Year |
|---|---|
[Analysis of dopamine transporter knockout mice as an animal model of AD/HD].
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Dopamine Plasma Memb | 2013 |
8 other studies available for nisoxetine and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinical; Mice | 2011 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
The discovery of Yuanzhi-1, a triterpenoid saponin derived from the traditional Chinese medicine, has antidepressant-like activity.
Topics: Animals; Antidepressive Agents; Citalopram; Cocaine; Depression; Disease Models, Animal; Female; Flu | 2014 |
Impaired cliff avoidance reaction in dopamine transporter knockout mice.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Avoidance Learning; Behavior, Animal; Diseas | 2013 |
Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac beta-adrenoceptor system in experimental heart failure.
Topics: Animals; Binding, Competitive; Cell Membrane; Disease Models, Animal; Eye Proteins; Fluoxetine; G-Pr | 2002 |
Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine.
Topics: alpha-Methyltyrosine; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Binding, Competit | 2008 |
Regional brain distribution of noradrenaline uptake sites, and of alpha1-alpha2- and beta-adrenergic receptors in PCD mutant mice: a quantitative autoradiographic study.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Autoradiography; Basal Ganglia; | 1999 |